Novocure (NVCR) Misses Q2 EPS by 8c

Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.23), $0.08 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $140.9 million versus the consensus estimate of $135.33 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
• FreeCast surges premarket; Accenture, Novocure slide